Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282946931> ?p ?o ?g. }
- W4282946931 endingPage "930" @default.
- W4282946931 startingPage "919" @default.
- W4282946931 abstract "Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly (ie, once every 3 weeks) carboplatin. However, this benefit was not observed in the previously reported progression-free survival results of ICON8. Here, we present the final coprimary outcomes of overall survival and updated progression-free survival analyses of ICON8.In this open-label, randomised, controlled, phase 3 trial (ICON8), women aged 18 years or older with newly diagnosed stage IC-IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (here collectively termed ovarian cancer, as defined by International Federation of Gynecology and Obstetrics [FIGO] 1988 criteria) and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited from 117 hospitals with oncology departments in the UK, Australia and New Zealand, Mexico, South Korea, and Ireland. Patients could enter the trial after immediate primary surgery (IPS) or with planned delayed primary surgery (DPS) during chemotherapy, or could have no planned surgery. Participants were randomly assigned (1:1:1), using the Medical Research Council Clinical Trials Unit at University College London randomisation line with stratification by Gynecologic Cancer Intergroup group, FIGO disease stage, and outcome and timing of surgery, to either 3-weekly carboplatin area under the curve (AUC)5 or AUC6 and 3-weekly paclitaxel 175 mg/m2 (control; group 1), 3-weekly carboplatin AUC5 or AUC6 and weekly paclitaxel 80 mg/m2 (group 2), or weekly carboplatin AUC2 and weekly paclitaxel 80 mg/m2 (group 3), all administered via intravenous infusion for a total of six 21-day cycles. Coprimary outcomes were progression-free survival and overall survival, with comparisons done between group 2 and group 1, and group 3 and group 1, in the intention-to-treat population. Safety was assessed in all patients who started at least one chemotherapy cycle. The trial is registered on ClinicalTrials.gov, NCT01654146, and ISRCTN registry, ISRCTN10356387, and is closed to accrual.Between June 6, 2011, and Nov 28, 2014, 1566 patients were randomly assigned to group 1 (n=522), group 2 (n=523), or group 3 (n=521). The median age was 62 years (IQR 54-68), 1073 (69%) of 1566 patients had high-grade serous carcinoma, 1119 (71%) had stage IIIC-IV disease, and 745 (48%) had IPS. As of data cutoff (March 31, 2020), with a median follow-up of 69 months (IQR 61-75), no significant difference in overall survival was observed in either comparison: median overall survival of 47·4 months (95% CI 43·1-54·8) in group 1, 54·8 months (46·6-61·6) in group 2, and 53·4 months (49·2-59·6) in group 3 (group 2 vs group 1: hazard ratio 0·87 [97·5% CI 0·73-1·05]; group 3 vs group 1: 0·91 [0·76-1·09]). No significant difference was observed for progression-free survival in either comparison and evidence of non-proportional hazards was seen (p=0·037), with restricted mean survival time of 23·9 months (97·5% CI 22·1-25·6) in group 1, 25·3 months (23·6-27·1) in group 2, and 24·8 months (23·0-26·5) in group 3. The most common grade 3-4 adverse events were reduced neutrophil count (78 [15%] of 511 patients in group 1, 183 [36%] of 514 in group 2, and 154 [30%] of 513 in group 3), reduced white blood cell count (22 [4%] in group 1, 80 [16%] in group 2, and 71 [14%] in group 3), and anaemia (26 [5%] in group 1, 66 [13%] in group 2, and 24 [5%] in group 3). No new serious adverse events were reported. Seven treatment-related deaths were reported (two in group 1, four in group 2, and one in group 3).In our cohort of predominantly European women with epithelial ovarian cancer, we found that first-line weekly dose-dense chemotherapy did not improve overall or progression-free survival compared with standard 3-weekly chemotherapy and should not be used as part of standard multimodality front-line therapy in this patient group.Cancer Research UK, Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, and Cancer Australia." @default.
- W4282946931 created "2022-06-16" @default.
- W4282946931 creator A5000009932 @default.
- W4282946931 creator A5001001032 @default.
- W4282946931 creator A5006305444 @default.
- W4282946931 creator A5010661421 @default.
- W4282946931 creator A5011138537 @default.
- W4282946931 creator A5012711576 @default.
- W4282946931 creator A5012713019 @default.
- W4282946931 creator A5014097745 @default.
- W4282946931 creator A5015650116 @default.
- W4282946931 creator A5016742379 @default.
- W4282946931 creator A5027988619 @default.
- W4282946931 creator A5031626579 @default.
- W4282946931 creator A5032801379 @default.
- W4282946931 creator A5033458280 @default.
- W4282946931 creator A5033928743 @default.
- W4282946931 creator A5040195796 @default.
- W4282946931 creator A5047381801 @default.
- W4282946931 creator A5049709430 @default.
- W4282946931 creator A5051525398 @default.
- W4282946931 creator A5052630297 @default.
- W4282946931 creator A5052709676 @default.
- W4282946931 creator A5056075088 @default.
- W4282946931 creator A5059722141 @default.
- W4282946931 creator A5065447416 @default.
- W4282946931 creator A5068550336 @default.
- W4282946931 creator A5070542581 @default.
- W4282946931 creator A5079383798 @default.
- W4282946931 creator A5081453094 @default.
- W4282946931 creator A5085574208 @default.
- W4282946931 creator A5088515280 @default.
- W4282946931 creator A5089242165 @default.
- W4282946931 creator A5089620663 @default.
- W4282946931 date "2022-07-01" @default.
- W4282946931 modified "2023-10-14" @default.
- W4282946931 title "Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial" @default.
- W4282946931 cites W1758017998 @default.
- W4282946931 cites W2007016674 @default.
- W4282946931 cites W2019607817 @default.
- W4282946931 cites W2070433490 @default.
- W4282946931 cites W2096235803 @default.
- W4282946931 cites W2097265582 @default.
- W4282946931 cites W2102306754 @default.
- W4282946931 cites W2105874372 @default.
- W4282946931 cites W2106767659 @default.
- W4282946931 cites W2114614279 @default.
- W4282946931 cites W2123528875 @default.
- W4282946931 cites W2123725304 @default.
- W4282946931 cites W2130349349 @default.
- W4282946931 cites W2130659669 @default.
- W4282946931 cites W2130806638 @default.
- W4282946931 cites W2145238269 @default.
- W4282946931 cites W2154885792 @default.
- W4282946931 cites W2164168201 @default.
- W4282946931 cites W2168893449 @default.
- W4282946931 cites W2222529560 @default.
- W4282946931 cites W2328421677 @default.
- W4282946931 cites W2329492928 @default.
- W4282946931 cites W2336410037 @default.
- W4282946931 cites W2588798733 @default.
- W4282946931 cites W2789849396 @default.
- W4282946931 cites W2900298813 @default.
- W4282946931 cites W2951586633 @default.
- W4282946931 cites W2951714360 @default.
- W4282946931 cites W2991621188 @default.
- W4282946931 cites W3012480421 @default.
- W4282946931 cites W3021056714 @default.
- W4282946931 cites W3028515504 @default.
- W4282946931 cites W3037255463 @default.
- W4282946931 cites W3083732107 @default.
- W4282946931 cites W4210987384 @default.
- W4282946931 cites W4255462147 @default.
- W4282946931 cites W69705680 @default.
- W4282946931 doi "https://doi.org/10.1016/s1470-2045(22)00283-2" @default.
- W4282946931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35690073" @default.
- W4282946931 hasPublicationYear "2022" @default.
- W4282946931 type Work @default.
- W4282946931 citedByCount "10" @default.
- W4282946931 countsByYear W42829469312022 @default.
- W4282946931 countsByYear W42829469312023 @default.
- W4282946931 crossrefType "journal-article" @default.
- W4282946931 hasAuthorship W4282946931A5000009932 @default.
- W4282946931 hasAuthorship W4282946931A5001001032 @default.
- W4282946931 hasAuthorship W4282946931A5006305444 @default.
- W4282946931 hasAuthorship W4282946931A5010661421 @default.
- W4282946931 hasAuthorship W4282946931A5011138537 @default.
- W4282946931 hasAuthorship W4282946931A5012711576 @default.
- W4282946931 hasAuthorship W4282946931A5012713019 @default.
- W4282946931 hasAuthorship W4282946931A5014097745 @default.
- W4282946931 hasAuthorship W4282946931A5015650116 @default.
- W4282946931 hasAuthorship W4282946931A5016742379 @default.
- W4282946931 hasAuthorship W4282946931A5027988619 @default.
- W4282946931 hasAuthorship W4282946931A5031626579 @default.
- W4282946931 hasAuthorship W4282946931A5032801379 @default.
- W4282946931 hasAuthorship W4282946931A5033458280 @default.
- W4282946931 hasAuthorship W4282946931A5033928743 @default.
- W4282946931 hasAuthorship W4282946931A5040195796 @default.